<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114491">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02145767</url>
  </required_header>
  <id_info>
    <org_study_id>PRMT15</org_study_id>
    <nct_id>NCT02145767</nct_id>
  </id_info>
  <brief_title>Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial</brief_title>
  <official_title>Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Miscarriages and preterm births are common and serious events affecting women, families, and
      healthcare systems on many levels. One of the risk factors for miscarriage and preterm birth
      is bleeding in the first trimester of pregnancy. Progesterone, a hormone that plays a key
      role during pregnancy, has been proposed as a possible medication to be used in pregnancy to
      prevent miscarriage and preterm birth among women who have bleeding in their first trimester
      of pregnancy. Unfortunately, unless sound clinical evidence is obtained through a clinical
      trial, whether or not progesterone can indeed prevent miscarriage and preterm birth remains
      uncertain and thus is not a recommended treatment in women with early pregnancy bleeding.
      The purpose of our study is to evaluate the effect of progesterone for the prevention of
      miscarriage and preterm birth among women with early pregnancy bleeding. We will carry out a
      clinical trial in which 850 women will be randomized to receive either progesterone
      supplementation (425 women) or a similarly appearing placebo (425 women) and the outcome of
      their pregnancy will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Miscarriage</measure>
    <time_frame>From 6-8 weeks of pregnancy until miscarriage</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occurrence of a miscarriage (&lt;20 weeks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>From 6-8 weeks of pregnancy until delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occurrence of preterm birth (&lt;37 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>From 6-8 weeks of pregnancy until 6 weeks post delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antenatal admissions, treatment of preterm labor etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcomes</measure>
    <time_frame>2 days to 6 weeks post delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Malformations, growth restriction, prematurity associated morbidity, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare outcomes</measure>
    <time_frame>From 6-8 weeks of pregnancy until 6 weeks post delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hospital costs, etc</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Miscarriage</condition>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar appearing suppository containing vehicle alone administered vaginally at bedtime until 34 completed weeks of pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <arm_group_label>Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Live intrauterine singleton pregnancy of &lt;14 weeks by crown-rump length on ultrasound
             with documented fetal cardiac activity

          -  Presence of a perigestational (subchorionic) hemorrhage on ultrasound

        Exclusion Criteria:

          -  Contraindication to Progesterone

          -  Any indication for progesterone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haim Abenhaim, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Oddy, MSc</last_name>
    <phone>514-340-8222</phone>
    <phone_ext>4199</phone_ext>
    <email>lisa.oddy@mail.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Klam, MD, FRCSC</last_name>
      <phone>514-340-3666</phone>
      <email>sklam@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Stephanie Klam</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Gagnon, MD, FRCS(c)</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>31385</phone_ext>
      <email>robert.gagnon@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Amira El-Messidi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Gagnon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Leroux, MD, FRCSC</last_name>
      <phone>514 345 4931</phone>
      <phone_ext>7768</phone_ext>
      <email>nathalielerouxmd@sympatico.ca</email>
    </contact>
    <investigator>
      <last_name>Francois Audibert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Leroux</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Haim Abenhaim</investigator_full_name>
    <investigator_title>Obstetrician &amp; Gynecologist, Maternal Fetal Medicine Specialist, Director of Perinatal Research</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
